MedTrace Logo

A Single Dose Study of SHR4640 in Healthy Male Volunteers

NCT03015948 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-07-03

No results posted yet for this study

Summary

This is a single-center, randomized, double-blind, placebo-controlled, single ascending-dose Phase I trial.

Conditions

Interventions

DRUG

SHR4640

a single dose of SHR4640 (n=8) for each dose cohort

DRUG

Placebo

a single dose of placebo (n=2) for each dose cohort .

Sponsors & Collaborators

  • Atridia Pty Ltd.

    lead INDUSTRY

Principal Investigators

  • Sam Salman, B.Sc,BMBS · Linear Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-22
Primary Completion
2016-11-23
Completion
2016-11-23

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03015948 on ClinicalTrials.gov